OncoBay Clinical

Innovative Infrastructure. Innovative Applications.

Built outside the conventional structure of a traditional CRO, OncoBay was designed from the outset to provide an innovative, streamlined focus on the execution of immuno-oncology programs while minimizing unnecessary and inefficient redundancies of systems, processes, and workforce. With our precise focus, we can provide our clients a team of highly experienced professionals with specialization in complex, early-phase oncology trials. OncoBay continues to provide unparalleled technological and professional expertise to accelerate the development of immunotherapies.

Learn our Capabilities

Experience is Our Cornerstone

Our mission and vision are to support the industry in accelerating development timelines to positively impact the lives of people with cancer. To this end, our organization is comprises experienced leaders in clinical oncology who are dedicated to making a difference. From individual team members on each project to the OncoBay leadership team, every component of our organization is committed to making an impact. In partnership with our parent company, the Moffitt Cancer Center, we are able to provide unmatched expertise to patients and sponsors.

Meet our Leadership

Not Just Any CRO

OncoBay is a boutique CRO designed to provide responsive, custom-curated services to biopharma and biotech companies seeking to overcome the hurdles of immuno-oncology clinical development. Comprehensive in our abilities, streamlined in our design, unrivaled in our expertise, and unbounded in our dedication to supporting drug developers in discovering cures for cancer, OncoBay provides our clients with quality results, greater speed, and unmatched value.

About Our Approach

Simplifying the Complex

Cancer Research Reimagined

Giving Cancer Research Every Advantage

Innovative Infrastructure. Innovative Applications.

Experience is Our Cornerstone

Not Just Any CRO

The Latest News & Events

Revolutionizing Cancer Treatment: OncoBay Clinical Joins The Leukemia & Lymphoma Society’s Beat AML® Master Clinical Trial

Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate, HSB-1216, an Anti-Cancer Mechanism

OncoBay Clinical and Clinscience Partner to Expand Immuno-oncology Research Globally

Take Advantage of OncoBay’s Innovative Approach

Submit a Request for Proposal